Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Lattice Biologics Ltd. (V:LBL)

Business Focus: Medical Devices & Implants

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LBL within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 03, 2020 00:09 ET
COVID19 UPDATE – Lattice Biologics Announces Cessation of Patient Recruitment
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces cessation of patient recruitment for its Phase 1 study.
Read full article
Aug 31, 2020 19:53 ET
Lattice Biologics Ltd. Reports Q3 2020 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for Q3 2020.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
1.42
1.42
10.40
Price to Book - most recent quarter
--
1.47
2.96
Price to Cash Flow per share - TTM
--
--
11.13
Price to Free Cash Flow per share - TTM
--
--
16.92
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 15, 202074,000-41,000
Aug 31, 2020115,00092,555
Aug 15, 202022,4455,168
See Short Report

Business Summary

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution

Lattice Biologics Ltd. (Lattice) is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company is a precision medicine company in the field of cellular therapies and tissue engineering, with a focus on bone, skin and cartilage regeneration. It produces and distributes multiple allograft tissue products used by surgeons as bone, skin and cartilage tissue void fillers. Its products include Acellular Demineralized Bone Scaffold, Demineralized Bone Matrix putty (DBM Putty), Acellular dermal matrix (ADM) dermal scaffold and Other Products. Its products are used in a range of applications, including enhancing fusion in spine surgery; enhancing breast reconstruction post mastectomy; sports medicine indications, including anterior cruciate ligament repair and promotion of bone growth in foot; promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries.

See business summary

 

Twitter

Search (past week) for $LBL.CA LBL.V

  • No tweets found